LUND, Sweden, Sept. 24, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) announced today that the
company launches a new concept for patient specific immunotherapy,
called Neo-X-Prime. Alligator presents the concept at the
scientific congress 11th World Bispecific Summit held September 22-24, 2020.
The new concept, based on Alligator's bispecific format
RUBY™, build on bispecific antibodies that physically connect tumor
debris from the patient's cancer cells with the relevant immune
cells, resulting in strong and tumor selective immune activation.
This is thought to increase both the accuracy of the immune attack,
and the overall anti-tumor effect. The issue with today's cancer
vaccines is that it is not obvious what structure the immune system
should be directed towards, and the vaccine must be produced
specifically for each single patient. In Alligator's concept, the
bispecific antibody could solve all this.
"The new concept may be viewed as a patient specific
therapeutic vaccination with the aim of curing cancer. The early
data are extremely promising and show that Neo-X-Prime
antibodies have the potential to induce anti-tumor effects superior
to any current treatment option", said Per Norlén, CEO at Alligator
Bioscience.
Today, September 24 at
5:20 pm CEST (1:20 pm EDT) Dr Peter
Ellmark, VP Discovery at Alligator, will give a presentation
with the title "Priming Neoantigen Specific T-Cells with a
Novel Bispecific Antibody". For further information, see
bispecific.com.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact person set out above, at 4:45 p.m. CEST
on September 24, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes five lead clinical and preclinical
drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527
(co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical
development by Shanghai Henlius Biotech Inc.). Alligator's shares
are listed on Nasdaq Stockholm (ATORX). The Company is
headquartered in Lund, Sweden. For
more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-launches-a-new-immuno-oncology-concept,c3202708
The following files are available for download:
https://mb.cision.com/Main/12681/3202708/1310573.pdf
|
Alligator Bioscience
launches a new immuno-oncology concept
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-launches-a-new-immuno-oncology-concept-301137640.html
SOURCE Alligator Bioscience